nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—ABCC1—Mitoxantrone—lymphatic system cancer	0.187	0.236	CbGbCtD
Atazanavir—ABCC1—Vincristine—lymphatic system cancer	0.129	0.163	CbGbCtD
Atazanavir—SLCO1B3—Methotrexate—lymphatic system cancer	0.113	0.142	CbGbCtD
Atazanavir—ABCC1—Methotrexate—lymphatic system cancer	0.0781	0.0985	CbGbCtD
Atazanavir—CYP2C9—Teniposide—lymphatic system cancer	0.0666	0.084	CbGbCtD
Atazanavir—ABCB1—Mitoxantrone—lymphatic system cancer	0.0452	0.057	CbGbCtD
Atazanavir—CYP3A4—Cytarabine—lymphatic system cancer	0.0393	0.0496	CbGbCtD
Atazanavir—CYP3A4—Teniposide—lymphatic system cancer	0.0387	0.0488	CbGbCtD
Atazanavir—ABCB1—Vincristine—lymphatic system cancer	0.0311	0.0392	CbGbCtD
Atazanavir—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0271	0.0342	CbGbCtD
Atazanavir—ABCB1—Methotrexate—lymphatic system cancer	0.0188	0.0238	CbGbCtD
Atazanavir—CYP3A4—Vincristine—lymphatic system cancer	0.0186	0.0235	CbGbCtD
Atazanavir—Hallucination—Carmustine—lymphatic system cancer	0.000455	0.00219	CcSEcCtD
Atazanavir—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000455	0.00219	CcSEcCtD
Atazanavir—Sweating—Mitoxantrone—lymphatic system cancer	0.000454	0.00219	CcSEcCtD
Atazanavir—Dyspnoea—Fludarabine—lymphatic system cancer	0.000452	0.00218	CcSEcCtD
Atazanavir—Haematuria—Mitoxantrone—lymphatic system cancer	0.000451	0.00218	CcSEcCtD
Atazanavir—Oedema peripheral—Carmustine—lymphatic system cancer	0.00045	0.00217	CcSEcCtD
Atazanavir—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000449	0.00217	CcSEcCtD
Atazanavir—Dyspepsia—Fludarabine—lymphatic system cancer	0.000446	0.00215	CcSEcCtD
Atazanavir—Decreased appetite—Fludarabine—lymphatic system cancer	0.000441	0.00213	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000438	0.00211	CcSEcCtD
Atazanavir—Fatigue—Fludarabine—lymphatic system cancer	0.000437	0.00211	CcSEcCtD
Atazanavir—Inflammation—Methotrexate—lymphatic system cancer	0.000434	0.0021	CcSEcCtD
Atazanavir—Hallucination—Vincristine—lymphatic system cancer	0.000434	0.00209	CcSEcCtD
Atazanavir—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000434	0.00209	CcSEcCtD
Atazanavir—Constipation—Fludarabine—lymphatic system cancer	0.000434	0.00209	CcSEcCtD
Atazanavir—Pain—Fludarabine—lymphatic system cancer	0.000434	0.00209	CcSEcCtD
Atazanavir—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000431	0.00208	CcSEcCtD
Atazanavir—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000429	0.00207	CcSEcCtD
Atazanavir—Urethral disorder—Vincristine—lymphatic system cancer	0.000428	0.00206	CcSEcCtD
Atazanavir—Eye disorder—Carmustine—lymphatic system cancer	0.000427	0.00206	CcSEcCtD
Atazanavir—Hypersensitivity—Teniposide—lymphatic system cancer	0.000425	0.00205	CcSEcCtD
Atazanavir—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000425	0.00205	CcSEcCtD
Atazanavir—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000423	0.00204	CcSEcCtD
Atazanavir—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000418	0.00202	CcSEcCtD
Atazanavir—Asthenia—Teniposide—lymphatic system cancer	0.000414	0.002	CcSEcCtD
Atazanavir—Malaise—Bleomycin—lymphatic system cancer	0.000411	0.00198	CcSEcCtD
Atazanavir—Pruritus—Teniposide—lymphatic system cancer	0.000408	0.00197	CcSEcCtD
Atazanavir—Cardiac disorder—Vincristine—lymphatic system cancer	0.000405	0.00195	CcSEcCtD
Atazanavir—Alopecia—Carmustine—lymphatic system cancer	0.000404	0.00195	CcSEcCtD
Atazanavir—Body temperature increased—Fludarabine—lymphatic system cancer	0.000401	0.00193	CcSEcCtD
Atazanavir—Mental disorder—Carmustine—lymphatic system cancer	0.0004	0.00193	CcSEcCtD
Atazanavir—Malnutrition—Carmustine—lymphatic system cancer	0.000398	0.00192	CcSEcCtD
Atazanavir—Cough—Bleomycin—lymphatic system cancer	0.000398	0.00192	CcSEcCtD
Atazanavir—Angiopathy—Vincristine—lymphatic system cancer	0.000396	0.00191	CcSEcCtD
Atazanavir—Diarrhoea—Teniposide—lymphatic system cancer	0.000395	0.0019	CcSEcCtD
Atazanavir—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000393	0.0019	CcSEcCtD
Atazanavir—Chest pain—Bleomycin—lymphatic system cancer	0.000388	0.00187	CcSEcCtD
Atazanavir—Myalgia—Bleomycin—lymphatic system cancer	0.000388	0.00187	CcSEcCtD
Atazanavir—Alopecia—Vincristine—lymphatic system cancer	0.000385	0.00186	CcSEcCtD
Atazanavir—Back pain—Carmustine—lymphatic system cancer	0.000385	0.00186	CcSEcCtD
Atazanavir—Discomfort—Bleomycin—lymphatic system cancer	0.000383	0.00185	CcSEcCtD
Atazanavir—Mental disorder—Vincristine—lymphatic system cancer	0.000382	0.00184	CcSEcCtD
Atazanavir—Urine output increased—Methotrexate—lymphatic system cancer	0.000381	0.00184	CcSEcCtD
Atazanavir—Ecchymosis—Methotrexate—lymphatic system cancer	0.000381	0.00184	CcSEcCtD
Atazanavir—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000381	0.00184	CcSEcCtD
Atazanavir—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000377	0.00182	CcSEcCtD
Atazanavir—Alopecia—Mitoxantrone—lymphatic system cancer	0.000375	0.00181	CcSEcCtD
Atazanavir—Confusional state—Bleomycin—lymphatic system cancer	0.000375	0.00181	CcSEcCtD
Atazanavir—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000374	0.0018	CcSEcCtD
Atazanavir—Oedema—Bleomycin—lymphatic system cancer	0.000372	0.00179	CcSEcCtD
Atazanavir—Infection—Bleomycin—lymphatic system cancer	0.000369	0.00178	CcSEcCtD
Atazanavir—Back pain—Vincristine—lymphatic system cancer	0.000367	0.00177	CcSEcCtD
Atazanavir—Vomiting—Teniposide—lymphatic system cancer	0.000367	0.00177	CcSEcCtD
Atazanavir—Agitation—Carmustine—lymphatic system cancer	0.000365	0.00176	CcSEcCtD
Atazanavir—Asthenia—Fludarabine—lymphatic system cancer	0.000364	0.00176	CcSEcCtD
Atazanavir—Rash—Teniposide—lymphatic system cancer	0.000364	0.00176	CcSEcCtD
Atazanavir—Dermatitis—Teniposide—lymphatic system cancer	0.000364	0.00175	CcSEcCtD
Atazanavir—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000362	0.00175	CcSEcCtD
Atazanavir—Headache—Teniposide—lymphatic system cancer	0.000362	0.00174	CcSEcCtD
Atazanavir—Pruritus—Fludarabine—lymphatic system cancer	0.000359	0.00173	CcSEcCtD
Atazanavir—Back pain—Mitoxantrone—lymphatic system cancer	0.000358	0.00173	CcSEcCtD
Atazanavir—Anorexia—Bleomycin—lymphatic system cancer	0.000354	0.00171	CcSEcCtD
Atazanavir—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000352	0.0017	CcSEcCtD
Atazanavir—Agitation—Vincristine—lymphatic system cancer	0.000349	0.00168	CcSEcCtD
Atazanavir—Photosensitivity—Methotrexate—lymphatic system cancer	0.000348	0.00168	CcSEcCtD
Atazanavir—Polyuria—Methotrexate—lymphatic system cancer	0.000348	0.00168	CcSEcCtD
Atazanavir—Diarrhoea—Fludarabine—lymphatic system cancer	0.000347	0.00167	CcSEcCtD
Atazanavir—Convulsion—Carmustine—lymphatic system cancer	0.000345	0.00166	CcSEcCtD
Atazanavir—Hypertension—Carmustine—lymphatic system cancer	0.000343	0.00166	CcSEcCtD
Atazanavir—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000343	0.00166	CcSEcCtD
Atazanavir—Nausea—Teniposide—lymphatic system cancer	0.000343	0.00165	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000339	0.00163	CcSEcCtD
Atazanavir—Chest pain—Carmustine—lymphatic system cancer	0.000339	0.00163	CcSEcCtD
Atazanavir—Myalgia—Carmustine—lymphatic system cancer	0.000339	0.00163	CcSEcCtD
Atazanavir—Anxiety—Carmustine—lymphatic system cancer	0.000337	0.00163	CcSEcCtD
Atazanavir—Malaise—Mitoxantrone—lymphatic system cancer	0.000333	0.00161	CcSEcCtD
Atazanavir—Dyspnoea—Bleomycin—lymphatic system cancer	0.000332	0.0016	CcSEcCtD
Atazanavir—Convulsion—Vincristine—lymphatic system cancer	0.000329	0.00159	CcSEcCtD
Atazanavir—Hypertension—Vincristine—lymphatic system cancer	0.000328	0.00158	CcSEcCtD
Atazanavir—Confusional state—Carmustine—lymphatic system cancer	0.000327	0.00158	CcSEcCtD
Atazanavir—Oedema—Carmustine—lymphatic system cancer	0.000325	0.00157	CcSEcCtD
Atazanavir—Decreased appetite—Bleomycin—lymphatic system cancer	0.000323	0.00156	CcSEcCtD
Atazanavir—Myalgia—Vincristine—lymphatic system cancer	0.000323	0.00156	CcSEcCtD
Atazanavir—Cough—Mitoxantrone—lymphatic system cancer	0.000323	0.00156	CcSEcCtD
Atazanavir—Infection—Carmustine—lymphatic system cancer	0.000322	0.00156	CcSEcCtD
Atazanavir—Vomiting—Fludarabine—lymphatic system cancer	0.000322	0.00156	CcSEcCtD
Atazanavir—Convulsion—Mitoxantrone—lymphatic system cancer	0.00032	0.00155	CcSEcCtD
Atazanavir—Rash—Fludarabine—lymphatic system cancer	0.00032	0.00154	CcSEcCtD
Atazanavir—Dermatitis—Fludarabine—lymphatic system cancer	0.000319	0.00154	CcSEcCtD
Atazanavir—Hypertension—Mitoxantrone—lymphatic system cancer	0.000319	0.00154	CcSEcCtD
Atazanavir—Pain—Bleomycin—lymphatic system cancer	0.000318	0.00153	CcSEcCtD
Atazanavir—Headache—Fludarabine—lymphatic system cancer	0.000318	0.00153	CcSEcCtD
Atazanavir—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000315	0.00152	CcSEcCtD
Atazanavir—Chest pain—Mitoxantrone—lymphatic system cancer	0.000315	0.00152	CcSEcCtD
Atazanavir—Myalgia—Mitoxantrone—lymphatic system cancer	0.000315	0.00152	CcSEcCtD
Atazanavir—Anxiety—Mitoxantrone—lymphatic system cancer	0.000314	0.00151	CcSEcCtD
Atazanavir—Discomfort—Mitoxantrone—lymphatic system cancer	0.000311	0.0015	CcSEcCtD
Atazanavir—Oedema—Vincristine—lymphatic system cancer	0.00031	0.00149	CcSEcCtD
Atazanavir—Anorexia—Carmustine—lymphatic system cancer	0.000309	0.00149	CcSEcCtD
Atazanavir—Infection—Vincristine—lymphatic system cancer	0.000308	0.00149	CcSEcCtD
Atazanavir—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000306	0.00148	CcSEcCtD
Atazanavir—Confusional state—Mitoxantrone—lymphatic system cancer	0.000304	0.00147	CcSEcCtD
Atazanavir—Nervous system disorder—Vincristine—lymphatic system cancer	0.000304	0.00147	CcSEcCtD
Atazanavir—Oedema—Mitoxantrone—lymphatic system cancer	0.000302	0.00146	CcSEcCtD
Atazanavir—Nausea—Fludarabine—lymphatic system cancer	0.000301	0.00145	CcSEcCtD
Atazanavir—Infection—Mitoxantrone—lymphatic system cancer	0.0003	0.00145	CcSEcCtD
Atazanavir—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0003	0.00145	CcSEcCtD
Atazanavir—Shock—Mitoxantrone—lymphatic system cancer	0.000297	0.00143	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000296	0.00143	CcSEcCtD
Atazanavir—Urticaria—Bleomycin—lymphatic system cancer	0.000295	0.00143	CcSEcCtD
Atazanavir—Anorexia—Vincristine—lymphatic system cancer	0.000295	0.00143	CcSEcCtD
Atazanavir—Body temperature increased—Bleomycin—lymphatic system cancer	0.000294	0.00142	CcSEcCtD
Atazanavir—Insomnia—Carmustine—lymphatic system cancer	0.000294	0.00142	CcSEcCtD
Atazanavir—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000293	0.00141	CcSEcCtD
Atazanavir—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000292	0.00141	CcSEcCtD
Atazanavir—Mood swings—Methotrexate—lymphatic system cancer	0.00029	0.0014	CcSEcCtD
Atazanavir—Dyspnoea—Carmustine—lymphatic system cancer	0.000289	0.0014	CcSEcCtD
Atazanavir—Somnolence—Carmustine—lymphatic system cancer	0.000289	0.00139	CcSEcCtD
Atazanavir—Anorexia—Mitoxantrone—lymphatic system cancer	0.000288	0.00139	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000282	0.00136	CcSEcCtD
Atazanavir—Decreased appetite—Carmustine—lymphatic system cancer	0.000282	0.00136	CcSEcCtD
Atazanavir—Insomnia—Vincristine—lymphatic system cancer	0.00028	0.00135	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00028	0.00135	CcSEcCtD
Atazanavir—Constipation—Carmustine—lymphatic system cancer	0.000278	0.00134	CcSEcCtD
Atazanavir—Pain—Carmustine—lymphatic system cancer	0.000278	0.00134	CcSEcCtD
Atazanavir—Breast disorder—Methotrexate—lymphatic system cancer	0.000276	0.00133	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000275	0.00133	CcSEcCtD
Atazanavir—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000274	0.00132	CcSEcCtD
Atazanavir—Decreased appetite—Vincristine—lymphatic system cancer	0.000269	0.0013	CcSEcCtD
Atazanavir—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000269	0.0013	CcSEcCtD
Atazanavir—Somnolence—Mitoxantrone—lymphatic system cancer	0.000268	0.00129	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000268	0.00129	CcSEcCtD
Atazanavir—Feeling abnormal—Carmustine—lymphatic system cancer	0.000267	0.00129	CcSEcCtD
Atazanavir—Fatigue—Vincristine—lymphatic system cancer	0.000267	0.00129	CcSEcCtD
Atazanavir—Asthenia—Bleomycin—lymphatic system cancer	0.000267	0.00129	CcSEcCtD
Atazanavir—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000266	0.00128	CcSEcCtD
Atazanavir—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000265	0.00128	CcSEcCtD
Atazanavir—Pain—Vincristine—lymphatic system cancer	0.000265	0.00128	CcSEcCtD
Atazanavir—Constipation—Vincristine—lymphatic system cancer	0.000265	0.00128	CcSEcCtD
Atazanavir—Pruritus—Bleomycin—lymphatic system cancer	0.000263	0.00127	CcSEcCtD
Atazanavir—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000262	0.00127	CcSEcCtD
Atazanavir—Eosinophilia—Methotrexate—lymphatic system cancer	0.000262	0.00126	CcSEcCtD
Atazanavir—Fatigue—Mitoxantrone—lymphatic system cancer	0.00026	0.00126	CcSEcCtD
Atazanavir—Pancreatitis—Methotrexate—lymphatic system cancer	0.000259	0.00125	CcSEcCtD
Atazanavir—Constipation—Mitoxantrone—lymphatic system cancer	0.000258	0.00125	CcSEcCtD
Atazanavir—Pain—Mitoxantrone—lymphatic system cancer	0.000258	0.00125	CcSEcCtD
Atazanavir—Body temperature increased—Carmustine—lymphatic system cancer	0.000257	0.00124	CcSEcCtD
Atazanavir—Abdominal pain—Carmustine—lymphatic system cancer	0.000257	0.00124	CcSEcCtD
Atazanavir—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000253	0.00122	CcSEcCtD
Atazanavir—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000249	0.0012	CcSEcCtD
Atazanavir—Neutropenia—Methotrexate—lymphatic system cancer	0.000247	0.00119	CcSEcCtD
Atazanavir—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000247	0.00119	CcSEcCtD
Atazanavir—Body temperature increased—Vincristine—lymphatic system cancer	0.000245	0.00118	CcSEcCtD
Atazanavir—Abdominal pain—Vincristine—lymphatic system cancer	0.000245	0.00118	CcSEcCtD
Atazanavir—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000244	0.00117	CcSEcCtD
Atazanavir—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000241	0.00116	CcSEcCtD
Atazanavir—Urticaria—Mitoxantrone—lymphatic system cancer	0.00024	0.00116	CcSEcCtD
Atazanavir—Hypersensitivity—Carmustine—lymphatic system cancer	0.000239	0.00115	CcSEcCtD
Atazanavir—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000239	0.00115	CcSEcCtD
Atazanavir—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000239	0.00115	CcSEcCtD
Atazanavir—Vomiting—Bleomycin—lymphatic system cancer	0.000236	0.00114	CcSEcCtD
Atazanavir—Depression—Methotrexate—lymphatic system cancer	0.000235	0.00113	CcSEcCtD
Atazanavir—Rash—Bleomycin—lymphatic system cancer	0.000234	0.00113	CcSEcCtD
Atazanavir—Dermatitis—Bleomycin—lymphatic system cancer	0.000234	0.00113	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000234	0.00113	CcSEcCtD
Atazanavir—Asthenia—Carmustine—lymphatic system cancer	0.000233	0.00112	CcSEcCtD
Atazanavir—Renal failure—Methotrexate—lymphatic system cancer	0.000232	0.00112	CcSEcCtD
Atazanavir—Stomatitis—Methotrexate—lymphatic system cancer	0.00023	0.00111	CcSEcCtD
Atazanavir—Hypersensitivity—Vincristine—lymphatic system cancer	0.000228	0.0011	CcSEcCtD
Atazanavir—Sweating—Methotrexate—lymphatic system cancer	0.000226	0.00109	CcSEcCtD
Atazanavir—Haematuria—Methotrexate—lymphatic system cancer	0.000225	0.00108	CcSEcCtD
Atazanavir—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000223	0.00108	CcSEcCtD
Atazanavir—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000222	0.00107	CcSEcCtD
Atazanavir—Asthenia—Vincristine—lymphatic system cancer	0.000222	0.00107	CcSEcCtD
Atazanavir—Diarrhoea—Carmustine—lymphatic system cancer	0.000222	0.00107	CcSEcCtD
Atazanavir—Nausea—Bleomycin—lymphatic system cancer	0.000221	0.00107	CcSEcCtD
Atazanavir—Asthenia—Mitoxantrone—lymphatic system cancer	0.000217	0.00104	CcSEcCtD
Atazanavir—Dizziness—Carmustine—lymphatic system cancer	0.000215	0.00104	CcSEcCtD
Atazanavir—Diarrhoea—Vincristine—lymphatic system cancer	0.000212	0.00102	CcSEcCtD
Atazanavir—Hepatitis—Methotrexate—lymphatic system cancer	0.000212	0.00102	CcSEcCtD
Atazanavir—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000209	0.00101	CcSEcCtD
Atazanavir—Urethral disorder—Methotrexate—lymphatic system cancer	0.000207	0.001	CcSEcCtD
Atazanavir—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000206	0.000996	CcSEcCtD
Atazanavir—Vomiting—Carmustine—lymphatic system cancer	0.000206	0.000996	CcSEcCtD
Atazanavir—Dizziness—Vincristine—lymphatic system cancer	0.000205	0.000989	CcSEcCtD
Atazanavir—Rash—Carmustine—lymphatic system cancer	0.000205	0.000987	CcSEcCtD
Atazanavir—Dermatitis—Carmustine—lymphatic system cancer	0.000204	0.000987	CcSEcCtD
Atazanavir—Headache—Carmustine—lymphatic system cancer	0.000203	0.000981	CcSEcCtD
Atazanavir—Erythema multiforme—Methotrexate—lymphatic system cancer	0.0002	0.000965	CcSEcCtD
Atazanavir—Eye disorder—Methotrexate—lymphatic system cancer	0.000198	0.000954	CcSEcCtD
Atazanavir—Tinnitus—Methotrexate—lymphatic system cancer	0.000197	0.000952	CcSEcCtD
Atazanavir—Vomiting—Vincristine—lymphatic system cancer	0.000197	0.000951	CcSEcCtD
Atazanavir—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000196	0.000948	CcSEcCtD
Atazanavir—Rash—Vincristine—lymphatic system cancer	0.000195	0.000943	CcSEcCtD
Atazanavir—Dermatitis—Vincristine—lymphatic system cancer	0.000195	0.000942	CcSEcCtD
Atazanavir—Headache—Vincristine—lymphatic system cancer	0.000194	0.000937	CcSEcCtD
Atazanavir—Nausea—Carmustine—lymphatic system cancer	0.000193	0.00093	CcSEcCtD
Atazanavir—Angiopathy—Methotrexate—lymphatic system cancer	0.000192	0.000926	CcSEcCtD
Atazanavir—Vomiting—Mitoxantrone—lymphatic system cancer	0.000192	0.000926	CcSEcCtD
Atazanavir—Immune system disorder—Methotrexate—lymphatic system cancer	0.000191	0.000922	CcSEcCtD
Atazanavir—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000191	0.00092	CcSEcCtD
Atazanavir—Rash—Mitoxantrone—lymphatic system cancer	0.00019	0.000918	CcSEcCtD
Atazanavir—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00019	0.000917	CcSEcCtD
Atazanavir—Headache—Mitoxantrone—lymphatic system cancer	0.000189	0.000912	CcSEcCtD
Atazanavir—Alopecia—Methotrexate—lymphatic system cancer	0.000187	0.000902	CcSEcCtD
Atazanavir—Mental disorder—Methotrexate—lymphatic system cancer	0.000185	0.000895	CcSEcCtD
Atazanavir—Malnutrition—Methotrexate—lymphatic system cancer	0.000184	0.000889	CcSEcCtD
Atazanavir—Nausea—Vincristine—lymphatic system cancer	0.000184	0.000888	CcSEcCtD
Atazanavir—Dysgeusia—Methotrexate—lymphatic system cancer	0.00018	0.00087	CcSEcCtD
Atazanavir—Nausea—Mitoxantrone—lymphatic system cancer	0.000179	0.000865	CcSEcCtD
Atazanavir—Back pain—Methotrexate—lymphatic system cancer	0.000178	0.00086	CcSEcCtD
Atazanavir—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000171	0.000825	CcSEcCtD
Atazanavir—Malaise—Methotrexate—lymphatic system cancer	0.000166	0.000802	CcSEcCtD
Atazanavir—Cough—Methotrexate—lymphatic system cancer	0.000161	0.000776	CcSEcCtD
Atazanavir—Convulsion—Methotrexate—lymphatic system cancer	0.00016	0.00077	CcSEcCtD
Atazanavir—Arthralgia—Methotrexate—lymphatic system cancer	0.000157	0.000757	CcSEcCtD
Atazanavir—Chest pain—Methotrexate—lymphatic system cancer	0.000157	0.000757	CcSEcCtD
Atazanavir—Myalgia—Methotrexate—lymphatic system cancer	0.000157	0.000757	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000156	0.000751	CcSEcCtD
Atazanavir—Discomfort—Methotrexate—lymphatic system cancer	0.000155	0.000748	CcSEcCtD
Atazanavir—Confusional state—Methotrexate—lymphatic system cancer	0.000152	0.000731	CcSEcCtD
Atazanavir—Infection—Methotrexate—lymphatic system cancer	0.000149	0.000721	CcSEcCtD
Atazanavir—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000147	0.000711	CcSEcCtD
Atazanavir—Skin disorder—Methotrexate—lymphatic system cancer	0.000146	0.000705	CcSEcCtD
Atazanavir—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000145	0.000701	CcSEcCtD
Atazanavir—Anorexia—Methotrexate—lymphatic system cancer	0.000143	0.000691	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000137	0.000661	CcSEcCtD
Atazanavir—Insomnia—Methotrexate—lymphatic system cancer	0.000136	0.000656	CcSEcCtD
Atazanavir—Dyspnoea—Methotrexate—lymphatic system cancer	0.000134	0.000647	CcSEcCtD
Atazanavir—Somnolence—Methotrexate—lymphatic system cancer	0.000134	0.000645	CcSEcCtD
Atazanavir—Dyspepsia—Methotrexate—lymphatic system cancer	0.000132	0.000639	CcSEcCtD
Atazanavir—Decreased appetite—Methotrexate—lymphatic system cancer	0.000131	0.000631	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00013	0.000626	CcSEcCtD
Atazanavir—Fatigue—Methotrexate—lymphatic system cancer	0.00013	0.000625	CcSEcCtD
Atazanavir—Pain—Methotrexate—lymphatic system cancer	0.000129	0.00062	CcSEcCtD
Atazanavir—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000124	0.000598	CcSEcCtD
Atazanavir—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000123	0.000593	CcSEcCtD
Atazanavir—Urticaria—Methotrexate—lymphatic system cancer	0.000119	0.000576	CcSEcCtD
Atazanavir—Abdominal pain—Methotrexate—lymphatic system cancer	0.000119	0.000573	CcSEcCtD
Atazanavir—Body temperature increased—Methotrexate—lymphatic system cancer	0.000119	0.000573	CcSEcCtD
Atazanavir—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000111	0.000534	CcSEcCtD
Atazanavir—Asthenia—Methotrexate—lymphatic system cancer	0.000108	0.00052	CcSEcCtD
Atazanavir—Pruritus—Methotrexate—lymphatic system cancer	0.000106	0.000513	CcSEcCtD
Atazanavir—Diarrhoea—Methotrexate—lymphatic system cancer	0.000103	0.000496	CcSEcCtD
Atazanavir—Dizziness—Methotrexate—lymphatic system cancer	9.94e-05	0.00048	CcSEcCtD
Atazanavir—Vomiting—Methotrexate—lymphatic system cancer	9.56e-05	0.000461	CcSEcCtD
Atazanavir—Rash—Methotrexate—lymphatic system cancer	9.48e-05	0.000457	CcSEcCtD
Atazanavir—Dermatitis—Methotrexate—lymphatic system cancer	9.47e-05	0.000457	CcSEcCtD
Atazanavir—Headache—Methotrexate—lymphatic system cancer	9.42e-05	0.000454	CcSEcCtD
Atazanavir—Nausea—Methotrexate—lymphatic system cancer	8.93e-05	0.000431	CcSEcCtD
